|
Affinity Purification of Biologics with Mimetope Peptides
|
1R43CA228945-01
|
$217,898
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-05
|
$826,500
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Metabolism Training Program
|
1T32CA221709-01A1
|
$201,444
|
ANN, DAVID
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-04
|
$604,525
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
|
5R01CA155769-07
|
$410,877
|
BADIE, BEHNAM
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
3R01CA197359-04S1
|
$68,577
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-04
|
$388,875
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Genetics Professional Education in a Global Community of Practice
|
2R25CA171998-06
|
$280,269
|
BLAZER, KATHLEEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Human natural killer cells: Advancing biology and clinical applications
|
7R35CA210087-02
|
$992,214
|
CALIGIURI, MICHAEL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia
|
4UH3CA213385-03
|
$87,498
|
CHEN, WENYONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-07
|
$369,725
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
|
5R01CA212119-02
|
$580,951
|
CHEN, YUAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
5R01CA214965-03
|
$444,571
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Menopausal transition - a window of susceptibility for the promotion of breast cancer by environmental exposures
|
5U01ES026137-04
|
$250,000
|
CHEN, SHIUAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
7R01CA211614-02
|
$475,560
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
|
5R01CA181045-05
|
$721,537
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER
|
5R00CA201075-04
|
$248,912
|
FENG, MINGYE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Integration of Palliative Care for Cancer Patients on Phase I Trials
|
5R01CA177562-05
|
$1,384,347
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Improving Patient-Centered Communication and Cancer Care
|
5R25CA174627-05
|
$264,960
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care
|
5R25CA217270-02
|
$310,771
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment
|
1R21CA223367-01
|
$242,633
|
HAHN, MARIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
MiRNAs in hepatocellular carcinoma development and treatment
|
5R01CA139158-07
|
$410,875
|
HUANG, WENDONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Geriatric Oncology: Educating nurses to improve quality care
|
5R25CA183723-04
|
$282,678
|
HURRIA, ARTI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Yes 2 Success
|
1R25CA233431-01
|
$485,999
|
KITTLES, RICK
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma
|
1R01CA215183-01A1
|
$529,603
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
5R01CA213131-02
|
$430,377
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
HDAC8 Mediated Regulation of Acute Myeloid Leukemia Pathogenesis and Maintenance
|
5R01CA178387-05
|
$317,475
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
5R01CA205247-02
|
$450,769
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Innovative Infrastructure to Enhance the California Teachers Study
|
5U01CA199277-04
|
$2,520,260
|
LACEY, JAMES
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
5R01CA201184-03
|
$549,553
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-06
|
$515,038
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Clinical Oncology Career Research Development Program
|
5K12CA001727-24
|
$919,727
|
MORTIMER, JOANNE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
5R01CA157644-09
|
$410,875
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Germline and Tumor Genomic Analyses of Breast Cancer in Latinas
|
5R01CA184585-05
|
$789,245
|
NEUHAUSEN, SUSAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN
|
5UM1CA186717-04
|
$2,015,876
|
NEWMAN, EDWARD
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs
|
1R21CA232275-01
|
$225,765
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
3R21CA205106-02S1
|
$77,331
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|